Summary of Purpose
This study will determine the safety of the drug Replagal or treating patients with Fabry disease, an inherited metabolic disorder. In this disease, an enzyme called Alpha-galactosidase A, which normally breaks down a fatty substance called globotriaosylceramide (Gb3), is missing or does not function properly. The resulting accumulation of Gb3 causes problems with the kidneys, heart, nerves, and blood vessels. ...Read More →
The following dates are available for this trial. Trial information last updated on 3 March 2008.
|1 Nov 2002||8 Nov 2002||Unavailable||1 Nov 2003||1 Nov 2003||Unavailable|
|Start Date||First Received||1st Completion||Completion||Verification||Results|
- Purpose: Treatment
- Endpoint: Safety/Efficacy Study